[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: Acceptance of regulatory submission in US for HER2 positive metastatic breast cancer previously treated with T-DM1 (based on DESTINY-Breast01 trial) in H2 2019 (AstraZeneca) - Apr 26, 2019 - Q1 2019 Results 
BLA
https://www.astrazeneca.com/investor-relations/results-and-presentations.html
 
Apr 26, 2019
 
 
83f46b7b-676c-4c03-8030-dbb609c96cbe.jpg